<DOC>
	<DOCNO>NCT01310803</DOCNO>
	<brief_summary>This Phase 3b open-label , randomize , parallel-arm , multicenter study evaluate efficacy safety 10 monthly intravesical administration maintenance therapy valrubicin follow induction valrubicin compare induction valrubicin subject CIS bladder . The randomization 1:1 subject stratified tumor type ( CIS plus papillary disease vs. CIS ) time last bacillus Calmette-Guerin ( BCG ) failure ( &gt; 1 year vs. &lt; 1 year ) .</brief_summary>
	<brief_title>Multi-center Study Evaluate Efficacy Safety Maintenance Therapy With Valrubicin Versus Maintenance , Subjects Treated With Valrubicin Induction Carcinoma Situ ( CIS ) Bladder</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Valrubicin</mesh_term>
	<criteria>1 . Is 18 year age old time consent sign 2 . Have histologically confirm diagnosis CIS bladder receive valrubicin induction therapy per label indication . 3 . Is diseasefree follow induction intravesical valrubicin Diseasefree define negative biopsy 10 12 week initiation valrubicin induction Valrubicin induction define receive least 3 6 weekly instillation 4 . Is available duration study include followup ( minimum 12 month randomization ) 5 . Have Eastern Cooperative Oncology Group ( ECOG ) performance status grade 2 less 6 . Have evidence urothelial carcinoma involve upper urinary tract prostatic urethra ( confirmed extravesical work , may include radiological image and/or biopsy ) within 6 month prior randomization 7 . Subjects ( male female ) childbearing potential ( include female subject postmenopausal less 1 year ) must willing practice abstinence effective contraception ( defined investigator ) study willing able continue contraception 30 day last dose study treatment 8 . Is able understand give write informed consent 1 . Have current previous history muscleinvasive bladder cancer ( MIBC ) 2 . Current previous history lymph node positive and/or metastatic bladder cancer 3 . Have current evidence pure squamous cell carcinoma , pure adenocarcinoma pure undifferentiated carcinoma bladder 4 . Is currently receive systemic anticancer therapy ( cytotoxic/cytostatic , immunotherapy radiation ) 5 . Received treatment investigational agent within 30 day 5 halflives prior randomization , whichever longer 6 . Received treatment intravesical chemotherapeutic agent ( valrubicin single administration mitomycin C posttransurethral resection bladder tumor [ TURBT ] ) within 3 month prior randomization 7 . Received treatment valrubicin induction within 3 month prior randomization 8 . Have contraindication valrubicin Known hypersensitivity anthracyclines polyoxyl castor oil Small bladder capacity , i.e . unable tolerate 75 mL instillation Concurrent urinary tract infection 9 . Absolute neutrophil count ( ANC ) &lt; 1000/ÂµL hemoglobin &lt; 10 g/dL 10 . Have active cardiovascular disease myocardial infarction within past 3 month , unstable angina pectoris , congestive heart failure ( NYHA Class III IV ) uncontrolled cardiac arrhythmia 11 . Female subject pregnant lactate 12 . Subjects childbearing potential unwilling practice abstinence effective contraception ( defined investigator ) study 30 day last dose study treatment 13 . Have current history document suspected malignancy organ system ( diagnose , treat untreated ) within past 5 year ( exception adequately treat basal cell squamous cell carcinoma skin asymptomatic nonmetastatic prostate cancer either previously successfully treat currently active surveillance receive hormone therapy ) 14 . Is unable tolerate intravesical administration intravesical surgical manipulation ( cystoscopy biopsy ) even premedication 15 . Have ongoing clinically significant active infection 16 . Have medical psychiatric condition , opinion investigator , would preclude participant adhere protocol complete trial per protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Urinary Bladder Neoplasms</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Urologic Neoplasms</keyword>
	<keyword>Urogenital Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Urinary Bladder Diseases</keyword>
	<keyword>Urologic Diseases</keyword>
	<keyword>TURBT</keyword>
	<keyword>Valstar</keyword>
</DOC>